January 15, 2026
Finance

Wall Street Analysts Cut Ratings on Key Stocks Including Rocket Lab and Albertsons

Recent Downgrades Highlight Shifting Sentiments on Select Public Companies

Loading...
Loading quote...

Summary

Several major Wall Street analysts have revised their recommendations on notable companies, including Rocket Lab Corp, Albertsons Companies Inc, MoonLake Immunotherapeutics, and Leslies Inc. These changes include multiple downgrades and adjustments to price targets, reflecting a more cautious outlook among financial experts for the near term.

Key Points

Goldman Sachs downgraded MoonLake Immunotherapeutics from Neutral to Sell despite raising the price target from $8 to $10.
Morgan Stanley lowered Leslies Inc’s rating from Equal-Weight to Underweight and cut the price target from $3.5 to $1.5.
Keybanc revised Rocket Lab Corp's rating from Overweight to Sector Weight without changing the price target.
Morgan Stanley also downgraded Albertsons Companies Inc from Equal-Weight to Underweight, reducing its price target from $20 to $14.

Recent activity across Wall Street has seen a number of top analysts reevaluate their positions on some frequently traded stocks. Specifically, notable adjustments have been made concerning Rocket Lab Corp (NASDAQ: RKLB), Albertsons Companies Inc (NYSE: ACI), MoonLake Immunotherapeutics (NASDAQ: MLTX), and Leslies Inc (NASDAQ: LESL).

Goldman Sachs analyst Richard Law took action on MoonLake Immunotherapeutics by lowering his rating from Neutral to Sell. Interestingly, this review accompanied an increase in the price target, which was raised from $8 to $10. At the close of trading on Wednesday, MoonLake's shares stood at $17.41, indicating a price well above this newly adjusted target.

On the other hand, Morgan Stanley analyst Simeon Gutman showed a diminished outlook for Leslies Inc by shifting his rating from Equal-Weight to Underweight. Alongside this downgrade, Gutman cut the price target for Leslies significantly, lowering it from $3.50 to $1.50. The stock price on Wednesday settled near this revised valuation, closing at $1.54.

Moving to Rocket Lab Corp, Keybanc analyst Michael Leshock moved the company's rating down from Overweight to Sector Weight. This downgrade marks a cautious step back on Rocket Lab amidst its closing stock price of $91.80 on Wednesday. No price target adjustment was disclosed alongside this rating change.

Similar in tone, Morgan Stanley's Simeon Gutman downgraded Albertsons Companies Inc’s rating from Equal-Weight to Underweight. Gutman also decreased the price target from $20 to $14. The retail grocery chain's shares finished Wednesday trading at $17.71, hovering between the previous and new price targets.

These analyst moves reflect a spectrum of perspectives on company prospects. The adjustments vary in degree but commonly signal increased guardedness regarding near-term performance or valuation.

Beyond the downgrades, market observers have noted emerging signals among certain stocks potentially gaining new momentum. Tools such as Benzinga’s Stock Whisper Index are designed to detect these subtle market shifts by analyzing proprietary data patterns, helping investors identify names gaining traction before becoming mainstream topics.

Current market data show key price moves surrounding these stocks: Albertsons’ shares showed a decline of 1.69% to $17.41; Leslies Inc dropped 1.30% to $1.52; MoonLake Immunotherapeutics fell 4.48% to $16.63; and Rocket Lab Corp saw a 1.94% decrease to $90.02.

Such analytical insights and real-time data assist market participants in navigating the evolving investment landscape by providing timely information on shifting analyst views and price movements.

Risks
  • Downgrades indicate increased analyst caution which could lead to further price pressure on affected stocks.
  • Discrepancies between current share prices and analyst price targets suggest volatility and uncertainty in valuation.
  • Market signals detected by specialized indexes point to emerging trends that may rapidly change stock trajectories.
  • Sector-specific risks may influence future analyst revisions beyond current assessments.
Disclosure
Education only / not financial advice
Search Articles
Category
Finance

Financial News

Ticker Sentiment
MLTX - negative LESL - negative RKLB - negative ACI - negative
Related Articles
Quince Therapeutics Experiences Massive Stock Surge Amid Strategic Advisor Engagement

Shares of Quince Therapeutics Inc (NASDAQ:QNCX) witnessed a remarkable surge of approximately 300% f...

Quest Diagnostics Reports Strong Q4 Earnings and Raises Full-Year Guidance Driving Stock Higher

Quest Diagnostics posted fourth-quarter results surpassing both earnings and revenue expectations, d...

Fiserv Reports Mixed Q4 2025 Results; Shares Rise on Earnings Beat

Fiserv, Inc. released its fiscal fourth-quarter 2025 financial results showing flat adjusted revenue...

Upstart Holdings Anticipates Q4 Earnings Release Amid Volatile Trading Dynamics

Upstart Holdings, Inc. (NASDAQ: UPST) is garnering considerable market attention as it prepares to a...

Dow Advances More Than 200 Points as Coca-Cola Reports Varied Q4 Performance

U.S. equity markets experienced a mixed session with the Dow Jones Industrial Average rising over 20...

Amazon's Investment Propels Beta Technologies Stock in After-Hours Trading

Beta Technologies Inc, an aerospace company specializing in electric aircraft and propulsion systems...